Acadian Asset Management LLC Autolus Therapeutics PLC Transaction History

Acadian Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.75 - $2.25 $17,207 - $22,124	-9,833 Reduced 44.64%	12,192 $22,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $38,323 - $72,021	22,025 New	22,025 $40,000
Q2 2022 Aug 09, 2022	BUY	$2.04 - $4.68 $71,171 - $163,275	34,888 New	34,888 $98,000
Q4 2021 Feb 10, 2022	SELL	$5.1 - $7.0 $159,573 - $219,023	-31,289 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.32 - $7.37 $166,457 - $230,599	31,289 New	31,289 $204,000
Q4 2020 Feb 11, 2021	SELL	$8.13 - $12.79 $16,764 - $26,372	-2,062 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$11.64 - $16.3 $25,992 - $36,397	-2,233 Reduced 51.99%	2,062 $24,000
Q2 2020 Aug 12, 2020	BUY	$5.38 - $16.14 $23,107 - $69,321	4,295 New	4,295 $69,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.